Regulation of the expression of cyclooxygenases and production of prostaglandin I2 and E2 in human coronary artery endothelial cells by curcumin

Journal of Physiology and Pharmacology

Volumn 62, Issue 1, 2011, Pages 21-28

  Tan, X ^a   Poulose, E M ^a   Raveendran, V V ^a   Zhu, B T ^a   Stechschulte, D J ^a   Dileepan, Kottarappat N ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Arachidonic acid; Curcumin; Cyclooxygenase; Endothelial cells; Microsomal PGE synthase 1; Prostaglandin I2; Prostaglandins; Synthase

Indexed keywords

ARACHIDONIC ACID; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MESSENGER RNA; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID;

ARTICLE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; CULTURE MEDIUM; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME BLOOD LEVEL; ENZYME INDUCTION; ENZYME SYNTHESIS; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MONOLAYER CULTURE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ARACHIDONIC ACID; CELLS, CULTURED; CORONARY VESSELS; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DINOPROSTONE; ENDOTHELIAL CELLS; EPOPROSTENOL; GENE EXPRESSION REGULATION; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES;

EID: 79954510797     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Singh. From exotic spice to modern drug. Cell 2007; 130: 765-768.
2. Gupta B, Ghosh B. Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int J Immunopharmacol 1999; 21: 745-757.
3. Jagetia GC, Aggarwal B.B. "Spicing up" of the immune system by curcumin. J Clin Immunol 2007; 27: 19-35.
4. Lee KW, Kim JH, Lee HJ, Surh YJ. Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-kappaB transcriptional activity in MCF10A human breast epithelial cells. Antioxid Redox Signal 2005; 7: 1612-1620.
5. Su CC, Chen GW, Lin JG, Wu LT, Chung JG. Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B /p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res 2006; 26: 1281-1288.
6. Park C, Kim GY, Kim GD, Choi BT, Park YM, Choi YH. Induction of G2/M arrest and inhibition of cyclooxygenase- 2 activity by curcumin in human bladder cancer T24 cells. Oncol Rep 2006; 15: 1225-1231.
7. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smokeinduced NF-kappaB activation through inhibition of NFkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003; 24: 1269-1279.
8. Cho JW, Park K, Kweon GR, et al. Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 2005; 37: 186-192.
9. Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008; 57: 1509-1517.
10. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004; 25: 1671-1679.
11. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
12. Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1991; 1083: 1-17.
13. Wu KK. Cyclooxygenase-2 induction in congestive heart failure: friend or foe? Circulation 1998; 98: 95-96.
14. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068.
15. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
16. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
17. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995; 75: 3A-10A.
18. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-277.
19. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-741.
20. Wong E, Huang JQ, Tagari P, Riendeau D. Effects of COX- 2 inhibitors on aortic prostacyclin production in cholesterolfed rabbits. Atherosclerosis 2001; 157: 393-402.
21. Olszanecki R, Jawien J, Gajda M, et al. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2005; 56: 627-635.
22. Tan X, Essengue S, Talreja J, Reese J, Stechschulte DJ, Dileepan KN. Histamine directly and synergistically with lipopolysaccharide stimulates cyclooxygenase-2 expression and prostaglandin I2 and E2 production in human coronary artery endothelial cells. J Immunol 2007; 179: 7899-7906.
23. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006; 106: 2503-2513.
24. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with highrisk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-2900.
25. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008; 267: 133-164.
26. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65: 1631-1652.
27. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. PNAS 1999; 96: 7220-7225.
28. Bulet L, Ouellet M, Bateman KP, et al. Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile. J Biol Chem 2004; 279: 23229-23237.
29. Koeberle A, Northoff H, Werz O. Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol Cancer Ther 2009; 8: 2348-2355.
30. Tourkina E, Gooz P, Oates JC, Ludwicka-Bradley A, Silver RM, Hoffman S. Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol Biol 2004; 31: 28-35.